Cytovation Announces Appointment of Ellen Lubman, MBA to its Board of Directors
December 20, 2023 03:00 ET
|
Cytovation
Bergen, Norway, December 20, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumour membrane immunotherapy CyPep-1, today...
Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors
October 11, 2023 03:00 ET
|
Cytovation
Findings confirm unique dual mechanism of action and fast-to-market target indication for potentially registrational trial All CICILIA trial endpoints met, with CyPep-1 demonstrating consistent...
Cytovation appoints Olav Hellebø to its Board of Directors
July 05, 2023 03:00 ET
|
Cytovation
Bergen, Norway, July 5th, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the...
Cytovation raises $8 million in Series A extension financing round for clinical advancement of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
June 02, 2023 03:00 ET
|
Cytovation
Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2, 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the...
Cytovation appoints Iman Barilero as Chief Development Officer
March 21, 2023 04:00 ET
|
Cytovation
Bergen, Norway, 21 March 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces that...
Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
February 15, 2023 03:00 ET
|
Cytovation
Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces...